Orrick and Cirio advised Ipsen on the deal, while Paul, Weiss, Rifkind, Wharton & Garrison and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Albireo. Ipsen...
You must be a Standard 1 Year member to access this content.
Orrick advised BioAtla on the deal. Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...
You must be a Standard 1 Year member to access this content.
Orrick advised Fisker on the deal. Fisker (NYSE: FSR) announced the establishment of its at-the-market equity program with J.P. Morgan Securities and Cowen and Company as...
You must be a Standard 1 Year member to access this content.
